EDIT - Editas Company Cash Volume

EDIT (Editas Medicine Inc) - company brandmark

The cash position of Editas Medicine, Inc. (EDIT) is clearly illustrated on the GURU.Markets trend chart, where 0.19 determines the latest valuation metric. Production relies on synthesis automation but requires the expertise of top medical professionals. A diversified portfolio of CRISPR drugs and partnerships with tech giants mitigate risks. A neutral geopolitical status in the US guarantees research stability without export restrictions.

Editas Medicine Inc - EDIT Company Cash Balance (period 07/04/2022 - 11/21/2026)

Editas Medicine (EDIT) - metric breakdowns and financial figures

- stock value and consensus price forecast:
Fundamental company analysis:editasmedicine.com EDIT
Signature product of editasmedicine.com

This indicator reflects the volume of liquid assets held by the company as recorded at the close of trading sessions. The metric is based on balance sheet data, measuring the issuer's ability to cover operating expenses without incurring external debt. The trend in the company's cash position demonstrates the business's financial resilience. Editas Medicine, Inc. (EDIT) allocates these reserves to pay for external laboratory services and contract manufacturers to accelerate the development of genomic technologies.

Main competitors

Company Cash Volume TEM|QGEN - Company Cash Reserve|ionispharma.com - Company Cash on Hand|Company Cash Balance RGEN|Avidity Corp - Company Cash Volume|CRISPR Therapeutics Corp - Company Total Cash Amount|GeneDx Holdings (WGS) - Company Cash Funds|Ultragenyx Pharmaceutical (RARE) - Company Cash Volume|Company Cash on Hand BEAM|Sarepta (SRPT) - Company Liquid Assets|Company Cash Funds Twist Bioscience Corp (TWST)|10x - Company Cash and Cash Equivalents|Company Cash Volume NTLA (intelliatx.com)|Company Total Cash Amount STOK (stoketherapeutics.com)|BioLife Solutions Inc - Company Cash Volume|WVE (Wave Life Sciences Ltd) - Company Cash and Cash Equivalents|Maze Therapeutics Corp (MAZE) - Company Cash Funds|Company Cash and Cash Equivalents SION|PRME (Prime Medicine Inc) - Company Cash Volume|Taysha Gene Therapies (TSHA) - Company Liquid Assets|Company Cash on Hand QURE (uniqure.com)|Company Total Cash Amount MGTX|Company Cash Volume RGNX (regenxbio.com)|SLDB: Company Cash and Cash Equivalents|ocugen.com - Company Cash Volume|PACB - Company Cash Volume|BNTC: Company Cash Volume|Company Cash and Cash Equivalents DSGN|Company Cash Funds Rocket Pharmaceuticals|Company Cash on Hand 4DMT (FDMT)|Company Cash Volume LXEO|Company Liquid Assets Korro Bio Inc.|Company Cash Funds Silence Therapeutics Inc. SLN|Company Cash Volume ProQR Therapeutics N.V. PRQR|CDXS: Company Cash on Hand|Company Cash Position Sangamo (SGMO)|NAUT (Nautilus Bio) - Company Cash on Hand|MGX - Company Liquid Assets|DTIL (Precision BioSciences Inc.) - Company Cash Volume|generationbio.com (GBIO) - Company Liquid Assets|Company Cash Funds Boundless Bio Inc (BOLD)|Company Cash Volume Exicure Inc. (XCUR)|Company Cash Funds imunon.com IMNN|Company Cash Volume Phio Pharmaceuticals PHIO|Mustang Bio Inc - Company Cash Volume|Company Cash Reserve transcodetherapeutics.com|BNGO: Company Cash Volume|Company Cash and Cash Equivalents APDN|BLUE (bluebirdbio.com) - Company Cash Volume|Company Cash Reserve ImmunoPrecise Antibodies IPA|Company Cash on Hand OMGA (omegatherapeutics.com)|Company Cash Volume Singular Genomics Systems, Inc. (OMIC)|Company Cash Volume RGLS (Regulus Therapeutics, Inc.)|Company Cash Volume Syros SYRS|Telesis Bio, Inc. - Company Cash Volume|TRACON Pharmaceuticals (TCON) - Company Cash on Hand|UBX: Company Cash Volume